Jubilant Ingrevia Posts Stable Q3 Revenue, Eyes CDMO Growth, Slashes Debt

CHEMICALS
Whalesbook Logo
AuthorIshaan Verma|Published at:
Jubilant Ingrevia Posts Stable Q3 Revenue, Eyes CDMO Growth, Slashes Debt
Overview

Jubilant Ingrevia reported stable Q3 FY26 total revenue at ₹1,051 Crore, down 1% YoY, but achieved 3% revenue growth for the nine-month period to ₹3,210 Crore. Despite pricing pressures, the company posted an 8% rise in EBITDA and PAT for 9M FY26 to ₹436 Crore and ₹191 Crore respectively, aided by strong volume growth and cost optimization. The company recommended an interim dividend of 250% (₹2.5 per share) and has significantly reduced net debt by 20% YoY to ₹544 Crore. Jubilant Ingrevia is strategically expanding its CDMO business with a major order delivery on track and a new plant construction, anticipating sustained growth from Specialty Chemicals and Nutrition segments.

📉 The Financial Deep Dive

Jubilant Ingrevia showcased resilience in its Q3 FY26 results, announcing stable total revenue of ₹1,051 Crore, a marginal 1% decrease year-on-year. However, the nine-month period ending December 31, 2025, saw revenue grow by 3% to ₹3,210 Crore. This stability was achieved despite softer pricing dynamics across its diverse business segments, with strong volume growth acting as a significant counter-balance.

The Numbers:

  • Revenue: Q3 FY26 stood at ₹1,051 Crore (-1% YoY). 9M FY26 revenue reached ₹3,210 Crore (+3% YoY).

  • EBITDA (9M FY26): ₹436 Crore (+8% YoY).

  • PAT (9M FY26): ₹191 Crore (+8% YoY). This growth was recorded after factoring in a one-time exceptional expense of ₹13 Crore related to amendments under the Indian Labor Code.

  • Margins: The Speciality Chemicals segment demonstrated robust performance, maintaining margins above 25% driven by a favorable product mix and effective cost optimization. The Nutrition business sustained healthy volume growth, though it faced pricing headwinds. Conversely, the Chemical Intermediates segment experienced a decline in EBITDA due to reduced sales and prevailing pricing pressures, particularly in European markets.

🚩 Risks & Outlook

Looking ahead to Q4 FY26, Jubilant Ingrevia anticipates a continuation of its growth momentum, primarily fueled by its Specialty Chemicals and Nutrition divisions. A partial recovery is expected within the Acetyls portfolio.

A key strategic focus is the acceleration of its Custom Development and Manufacturing Organization (CDMO) segment. The company is on track to commence delivery of a significant CDMO order and has initiated the construction of a new multipurpose plant in Gajraula, India.

The outlook for the pharmaceutical and agrochemical sectors, which are end-markets for some of Jubilant Ingrevia's products, is cautiously optimistic. Forecasts suggest potential market improvements due to Free Trade Agreements (FTAs) and a steady recovery in volumes, respectively.

Financially, the company has made substantial progress in deleveraging, with net debt reduced by 20% year-on-year to ₹544 Crore as of December 31, 2025. Significant results have also been observed in working capital optimization initiatives. Capital expenditure for Q3 FY26 was ₹265 Crore, and ₹366 Crore for the first nine months of FY26, largely allocated to plant expansions designed to support future growth.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.